La vendita allo scoperto per Exail Technologies dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Exail Technologies. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Exail Technologies (OTC:EXALF) Azioni, Report sulle vendite allo scoperto

Exail Technologies SA is a France-based company specializing in the robotics industry and in the production of automated systems. The company's segments include Engineering and Protection Systems; Drones and Systems and Structure and disposals. It generates maximum revenue from the Drones and Systems segment.

Exail Technologies SA

Earnings

Earnings Beats

News

Vitesse Energy Q2 Adj. EPS $0.45, Sales $81.755M Beat $69.780M Estimate

Contracts

LPRO

Open Lending Announces Early Extension Of AmTrust Producer Agreement With AmTrust North America, Set To Run Through 2033

ONEOK Q2 Sales $7.887B Beat $7.131B Estimate

Tidewater (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of $0.54 by 171.38 percent. This is a 55.32 percent increase over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $341.40 million which beat the analyst consensus estimate of $322.18 million by 5.96 percent. This is a 0.64 percent increase over sales of $339.23 million the same period last year.

Tidewater Q2 EPS $1.46 Beats $0.54 Estimate, Sales $341.40M Beat $322.18M Estimate

WIIM

DORM

Dorman Products shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance above estimates.

General

SATL

Satellogic Expands Agreement With HEO; Under The New Agreement, HEO Receives Exclusive Access To Satellogic's High-Resolution Constellation For Capturing NEI, Supporting Rapid-Response Monitoring Of Space Objects

TREX

Trex shares are trading lower after the company issued Q3 revenue guidance with its midpoint below estimates.

ODDITY Tech shares are trading lower after the company issued FY25 guidance with midpoints below estimates.

Currenc Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.04) by 150 percent. The company reported quarterly sales of $8.71 million which missed the analyst consensus estimate of $10.40 million by 16.23 percent.

Earnings Misses

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

Currenc Group Q2 EPS $(0.10) Misses $(0.04) Estimate, Sales $8.71M Miss $10.40M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furl.avanan.click%2Fv2%2F___http%3A%2Fwww.heliostechnologies.com___.YXAzOmtlaWFkdmlzb3JzOmE6bzphNTEwZmNmMjRiNzQwOWQxNjcwNGFjOTcyMjUxOGQ5Njo2OmZiN2Y6YjhmNjVmYzJmYjE0NzI0ZjcxY2VhYzM4MTI0MmFjOTIyZGQ1MjcxN2Q5ZTFlOTA5NGI0YWRjNzhhNWNlYWQzYjpwOlQ6Rg&amp;esheet=54302572&amp;newsitemid=20250804588777&amp;lan=en-US&amp;anchor=Helios+Technologies&amp;index=1&amp;md5=6381a84ec4b1faecae305044cad469d1">Helios Technologies</a>, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) ("Helios" or the "Company"), a global leader in highly engineered motion control and electronic controls technology, announced today that it has executed a definitive agreement for the sale of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.custom.com.au%2F&amp;esheet=54302572&amp;newsitemid=20250804588777&amp;lan=en-US&amp;anchor=Custom+Fluidpower&amp;index=2&amp;md5=53ed20a75962564248ba41163c32fda4">Custom Fluidpower</a> ("CFP") to <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.questas.com.au%2F&amp;esheet=54302572&amp;newsitemid=20250804588777&amp;lan=en-US&amp;anchor=Questas+Group&amp;index=3&amp;md5=8f8513833a36bc361af2af570cc195de">Questas Group</a> ("Questas"). The all-cash transaction valued at approximately $83 million AUD (~$54 million USD) is subject to final working capital and other customary closing adjustments. The transaction value represents an increase of approximately $48 million AUD above the acquisition price paid for CFP by the Company in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heliostechnologies.com%2Fnews%2Fpress-releases%2Fdetail%2F137%2Fhelios-technologies-completes-acquisition-of-custom&amp;esheet=54302572&amp;newsitemid=20250804588777&amp;lan=en-US&amp;anchor=August+2018&amp;index=4&amp;md5=59e7a9c077aa925c8e945ec61d306300">August 2018</a>. Questas, is headquartered in Sydney, Australia, and has approximately 850 employees across 37 locations. Helios will also enter into a long-term exclusive distribution agreement with Questas, subject to annual growth targets tied to market conditions, assuring the continuity of Sun Hydraulics' strategic position in the Australian hydraulics market through CFP's extensive engineering, distribution, and service network.

Asset Sales

HLIO

Helios Technologies Enters Into A Definitive Agreement To Sell Custom Fluidpower To Australia-Based Questas Group In An All-cash Deal Valued At ~$54M Usd)

INSP

Inspire Medical Systems shares are trading lower after the company reported worse-than-expected Q2 GAAPEPS results and cut its FY25 guidance below estimates.

MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) reported quarterly earnings of $10.31 per share which missed the analyst consensus estimate of $12.00 by 14.1 percent. This is a 1.62 percent decrease over earnings of $10.48 per share from the same period last year. The company reported quarterly sales of $6.790 billion which beat the analyst consensus estimate of $6.557 billion by 3.55 percent. This is a 33.85 percent increase over sales of $5.073 billion the same period last year.

MELI

MercadoLibre Q2 EPS $10.31 Misses $12.00 Estimate, Sales $6.790B Beat $6.557B Estimate

<ul>
<li>First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines Program
<ul>
<li>Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to manage PYRUKYND commercialization in the Gulf Region&nbsp;</li>
</ul>
</li>
</ul>

Biotech

Government

Regulations

AGIO

Saudi Food And Drug Authority Approves Agios' PYRUKYND For Adults With Thalassemia

Management

ICHR

Ichor Holdings' Jeff Andreson And The Board Of Directors Agree To A CEO Transition Plan;  Mr.Andreson Will Continue As Ceo Until His Successor Is Named

Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) raises FY2025 Adj EPS guidance from $4.85-$5.10 to $5.12-$5.34 vs $5.01 analyst estimate. Raises FY2025 sales outlook from $5.850 billion-$5.925 billion to $5.880 billion-$5.980 billion vs $5.892 billion estimate.

Guidance

Encompass Health Raises FY2025 Adj EPS Guidance from $4.85-$5.10 to $5.12-$5.34 vs $5.01 Est; Raises FY2025 Sales Guidance from $5.850B-$5.925B to $5.880B-$5.980B vs $5.892B Est

Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.21 by 15.99 percent. This is a 26.13 percent increase over earnings of $1.11 per share from the same period last year. The company reported quarterly sales of $1.458 billion which beat the analyst consensus estimate of $1.427 billion by 2.20 percent. This is a 12.07 percent increase over sales of $1.301 billion the same period last year.

Encompass Health Q2 Adj. EPS $1.40 Beats $1.21 Estimate, Sales $1.458B Beat $1.427B Estimate

Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) reported quarterly earnings of $0.22 per share which missed the analyst consensus estimate of $0.24 by 10.2 percent. This is a 12 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $323.00 million which missed the analyst consensus estimate of $338.65 million by 4.62 percent. This is a 2.79 percent increase over sales of $314.23 million the same period last year.

CRD/B

Crawford & Company Common Stock Q2 Adj. EPS $0.22 Misses $0.24 Estimate, Sales $323.00M Miss $338.65M Estimate

RAIL

Freightcar America shares are trading higher following better-than-expected Q2 financial results.

LTC Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) raises FY2025 FFO guidance from $2.65-$2.69 to $2.67-$2.71 vs $2.63 analyst estimate..

LTC Properties Raises FY2025 FFO Guidance from $2.65-$2.69 to $2.67-$2.71 vs $2.63 Est

Primoris Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) raises FY2025 Adj EPS guidance from $4.20-$4.40 to $4.90-$5.10..

Comments

Exail Technologies

Vendite allo scoperto

Exail Technologies (OTC:EXALF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO